An athlete’s take on microdosing
Microdosing Mushrooms: Athlete Perspectives on the Psychedelic Supplement A tiny dose of magic mushrooms might
July 4, 2022
Microdosing Mushrooms: Athlete Perspectives on the Psychedelic Supplement A tiny dose of magic mushrooms might
Numinus Pilots Mental Health Program for Corporate Clients in Utah With companies investing more and
Natural language signatures of psilocybin microdosing The benefits of microdosing can be so subtle that
Tryp Therapeutics Announces Results of First Patient Dosed in Its Phase II Clinical Trial for
Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for
A New Clinical Trial in South Africa Aims to Study the Effect of Psilocybin on
UNITy: World’s first study of how DMT-induced brain changes predict improved wellbeing University College London
Why ketamine is a speedster antidepressant Several studies have found that ketamine produces a rapid
Silo Wellness To Acquire Canadian Dyscovry Science, Producer Of Psilocybin For IBS Treatment Shrooms are
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program Ceruvia Lifesciences
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment
Global Wellness Readies for First Clinical Trial Could your next surgery involve MDMA? Shanti Therapeutics
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Red Light Holland Files International Patent Application for ‘Find Your Dose’ Customization of Microdosing Kits
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults COMPASS Pathways (CMPS) is
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects
If you’ve been wanting to try psychedelic therapy legally, now’s your chance! Johns Hopkins is
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant
Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip
A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation
Here’s two new opportunities to get your research funded: COMPASS Pathways (CMPS) is sponsoring three
Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke Ninnion